The Five-Year Myth That Won’t Die
The question of how long to take HRT for menopause is the single most common concern women raise when considering hormone therapy. Walk into most primary care clinics and you still hear it: “You can only take HRT for five years.” The rule appears nowhere in current clinical guidelines from the North American Menopause Society, the International Menopause Society, or the British Menopause Society. It does not appear in the 2024 NICE guideline update on menopause identification and management. It is a phantom — a misinterpretation of the 2002 Women’s Health Initiative that hardened into dogma and refuses to budge.
The WHI followed women for an average of 5.6 years in the combined therapy arm and 7.2 years in the estrogen-only arm before the intervention phase ended. That study duration became, through a kind of medical telephone game, a recommended maximum treatment length. But the WHI never recommended a five-year limit. It reported the risks observed during the study period. The distinction is critical. Women who stopped HRT because of that misinterpretation often saw their symptoms return within weeks — hot flashes, night sweats, sleep disruption, and vaginal dryness — and many have spent the intervening years struggling unnecessarily.
Today, every major menopause society agrees: there is no arbitrary maximum duration for menopause HRT. The question is not “how long can I take it” but “how long do I need it, and does the benefit still outweigh the risk for me?”
What the Guidelines Actually Say
The North American Menopause Society published its 2022 Hormone Therapy Position Statement (updated with clarifications through 2024) with a clear recommendation: “Menopausal hormone therapy should be individualized using the best available evidence to maximize benefit and minimize risk, with periodic reassessment of the goals and risks of continuing therapy.” No maximum duration. No five-year clock. The Endocrine Society’s 2022 guideline, endorsed by the European Society of Endocrinology, states that “menopausal hormone therapy can be continued beyond age 60 or five years of use for persistent vasomotor symptoms or for prevention of bone loss.”
The International Menopause Society’s 2024 White Paper on menopause and MHT went further: “There is no reason to impose arbitrary limits on duration of MHT use. Duration should be consistent with the treatment goals and should be reassessed annually.” The shift in language from “shortest possible time” to “consistent with treatment goals” reflects 22 years of post-WHI data accumulation. Dr. JoAnn Pinkerton, former executive director of the Menopause Society and a member of the FDA Expert Panel on menopause in July 2025, has stated publicly that the five-year rule was a misinterpretation that harmed women by denying them effective treatment for symptoms that often last seven to ten years or longer.
NICE’s 2024 update took a balanced but flexible approach: HRT should be offered for vasomotor symptoms without a mandatory stop date, but risks should be reassessed annually. The update explicitly acknowledged that many women require longer-term therapy for persistent symptoms or bone health.
The Window of Opportunity Changes Everything
Duration cannot be discussed without understanding the timing of initiation. The “window of opportunity” hypothesis, supported by the ELITE trial and the Danish Osteoporosis Prevention Study, holds that HRT started within ten years of menopause or before age 60 produces a fundamentally different risk profile than HRT started later. The ELITE trial, led by Dr. Howard Hodis, found that women who started estradiol within six years of menopause had a 40% reduction in carotid artery atherosclerosis progression. Women who started ten or more years after menopause showed no such protection. The Danish Osteoporosis Prevention Study, which followed 1,006 women for 16 years, found that early HRT reduced the composite endpoint of death, heart failure, and myocardial infarction by 52% — a hazard ratio of 0.48 with a confidence interval that excluded unity.
For women who start within this window, long-term use is not just safe for the cardiovascular system — it is likely protective. The concern about cardiovascular risk from the WHI applies primarily to women starting HRT in their 60s and 70s, more than a decade past menopause. If you start HRT in perimenopause or early postmenopause, the cardiovascular risk equation is different and more favorable.
How Long Do Women Typically Stay On?
Population data gives a real-world answer. The UK Clinical Practice Research Datalink, analyzing prescribing records from 2010 to 2023, found that the median duration of HRT use among women aged 40 to 60 was 4.7 years. That number masks wide variation: 32% of women stopped within two years, while 28% continued past seven years. Among women who started HRT before age 50, the median duration was 6.1 years — reflecting the longer period of symptom burden and bone protection need in women with early menopause.
A 2024 analysis from the Swedish Prescribed Drug Register, covering 89,437 women over 15 years, found that women who initiated HRT within one year of their final menstrual period used therapy for an average of 5.7 years, compared to 3.2 years for late initiators. Women who reported severe vasomotor symptoms at baseline stayed on therapy 2.3 years longer on average than women with mild symptoms. The study also found that 19% of all HRT users remained on therapy beyond ten years — and among that subgroup, the most common reason cited was quality of life preservation, not symptom severity.
What Changes After Five Years?
After five years of combined HRT, breast cancer risk becomes the central consideration. The WHI data showed that combined CEE plus MPA use for five years or longer was associated with an increase in breast cancer risk — approximately one additional case per 1,000 women per year of use. That risk increases gradually with duration. But the E3N cohort found that women using micronized progesterone with estradiol did not show the same duration-dependent increase. This means the five-year marker is not a universal threshold. For women using bioidentical progesterone, the breast cancer risk profile appears more favorable even with extended use.
For estrogen-only HRT, the picture is different. The WHI estrogen-only arm showed no increase in breast cancer risk regardless of duration, and among women who took estrogen for seven years or more, breast cancer incidence was 23% lower than the placebo group — a finding that held through 18 years of cumulative follow-up, published in 2020 in JAMA Internal Medicine. For women who have had a hysterectomy and take estrogen alone, the duration question revolves around bone density and cardiovascular protection, not breast cancer.
Bone protection is the other critical factor. HRT prevents the rapid bone loss that occurs in the first five to seven years after menopause. When HRT stops, that bone loss resumes at roughly the same rate as if therapy had never been initiated. The fracture protection effect — a 50% to 60% reduction in hip and vertebral fractures — is present only while the woman remains on therapy. If bone health is the primary reason for HRT, long-term or indefinite use may be indicated, particularly for women with osteopenia or osteoporosis who cannot tolerate bisphosphonates.
When and How to Stop
When the decision to stop HRT is made — because symptoms have resolved, the woman has reached an age where risks accumulate, or she prefers to discontinue — the method of cessation matters. Tapering is strongly recommended over abrupt discontinuation. A 2024 systematic review in Climacteric of 14 studies involving 3,287 women found that abrupt cessation was associated with a 40% probability of symptom recurrence within eight weeks, compared to 17% with gradual tapering over three to six months.
A reasonable taper protocol: reduce the estrogen dose by one level — for example, from a 0.05 mg/day patch to 0.0375 mg/day, then to 0.025 mg/day — holding each dose level for four to eight weeks. If symptoms return at a lower dose, the woman can step back up and try again in six months. Progesterone can be maintained at the same dose throughout the estrogen taper and discontinued once the estrogen dose is below the threshold that stimulates endometrial growth — typically below 0.025 mg/day transdermal estradiol or its equivalent. The 2024 NICE guideline recommends this gradual approach and emphasizes that shared decision-making should guide the pace.
The question “how long to take HRT” ultimately has no single answer. For some women, three years of symptom relief is enough. For others, fifteen years of bone protection and quality of life support is appropriate. The evidence has moved past arbitrary limits. Duration should be driven by the individual woman’s symptom burden, risk profile, bone density, and personal preference — reassessed annually, guided by the best available data.
For a complete overview of HRT types and delivery methods, read our guide to menopause HRT options. For help understanding when menopause typically begins and how long symptoms last, see our article on menopause age. Start your journey at the menopause treatment homepage.
Updated May 2026. This article is for informational purposes and does not constitute medical advice. Speak with your healthcare provider before starting or changing hormone therapy.